Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1229 clinical trials
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

recurrent ewing sarcoma
measurable disease
neutrophil count
bone marrow procedure
cytokines
  • 0 views
  • 19 Feb, 2024
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

This prospectivemulti-centeropen-label, controlled study will evaluate the efficacy and safety of targeted drug in combination with CHOP in treatment of newly diagnosed peripheral T-cell lymphoma.

measurable disease
pet/ct scan
lymphoma
peripheral t-cell lymphoma
t-cell lymphoma
  • 0 views
  • 19 Feb, 2024
Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.

azacitidine
measurable disease
tucidinostat
chidamide
lymphoma
  • 0 views
  • 19 Feb, 2024
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

cyclophosphamide
lymphoma
marginal zone lymphoma
prednisone
epirubicin
  • 0 views
  • 19 Feb, 2024
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma

This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.

biological therapy
measurable disease
positron emission tomography
neutrophil count
glucocorticoids
  • 0 views
  • 19 Feb, 2024
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

A study of CT-RD06 cell injection in patients with relapsed or refractory CD19+ B-cell hematological malignancy.

flow cytometry
leukemia
oxygen saturation
lymphoma
cancer
  • 0 views
  • 19 Feb, 2024
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

flow cytometry
lymphoblastic lymphoma
oxygen saturation
leukemia
lymphoma
  • 0 views
  • 19 Feb, 2024
Ibrutinib + Venetoclax in Untreated WM

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this …

absolute neutrophil count
measurable disease
platelet transfusion
myd88 gene mutation
waldenstrom's macroglobulinemia
  • 0 views
  • 19 Feb, 2024
A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma

Using single-cell RNA sequencing, this study will explore the heterogeneity of lymphoma inside and outside the lymph node, identify tumor specific molecular markers and cell subgroups, explore the differences in tumor microenvironment composition, and provide a basis for diagnosis and precision treatment.

non-hodgkin lymphoma
hodgkin's disease
lymphoma
  • 0 views
  • 19 Feb, 2024